Frontlight ResearchEarly access
WithdrawnPhase 1/2
Immunomodulation Using VB-201 to Reduce Arterial Inflammation in Treated HIV - VITAL HIV Trial
Key facts
- Who runs it
- Priscilla Hsue, MD
- Where
- San Francisco, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 1/2
- Started
- 1 Jul 2022
- Expected to end
- 1 Jul 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- VB-201
- Placebo
- Record updated
- 15 September 2022
- Why it stopped
- Funding for this trial has not been established.
Who can take part
- Age
- 40 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Documented HIV infection
- On continuous antiretroviral therapy and virologically suppressed HIV infection for ≥12 weeks prior to study entry
- CD4 T-cell count > 350 cells/mm3
- Male or female between the ages ≥ 40 years of age to <≤75
- Documented cardiovascular disease (1. Prior myocardial infarction, 2. History of percutaneous coronary intervention, 3. History of coronary artery bypass graft OR 4. Angiographic evidence of >50% stenosis in at least one coronary artery] OR 1 CVD risk factor (T2DM, current smoking, hypertension, dyslipidemia, hsCRP≥2mg/L, family history)
- TBR of >1.6 of the MDS of the carotid/aorta at baseline. This baseline arterial TBR cutoff excludes the rare individual that lacks appreciable arterial inflammation. It is notable that while 5-10% of uninfected individuals will have lower TBRs, it is rare that an HIV infected individual will fall below this range
- Female subjects must either be of non-childbearing potential as defined by menopause with amenorrhea for >2 years, bilateral oophorectomy, or agree to use adequate contraception throughout the study and for at least one month following termination and have a negative pregnancy test at screening prior to the first dose of drug
- Males must use at least one method of contraception throughout the study
Who cannot take part
- Evidence of tuberculosis infection at screening within 30 days prior to screening
- On additional immunosuppressant or immunomodulatory therapies
- Uncontrolled hypertension or diabetes requiring insulin
- Cancer within the last 5 years with exception of squamous cell carcinoma and basal cell carcinoma
- Acute systemic infection within 30 days
- AST/ALT or alkaline phosphatase >2x ULN
- Nephrotic syndrome or eGFR <60 mL/min/1.73m2
- Cytopenias which include 1) WBC <3.5 x103/uL 2) Platelet <120 x103/uL 3) ANC <1.5 x103/uL, and absolute lymphocytes <0.8 x 103/uL
- Anemia as fined by <10 g/dL
- Family history of long QT syndrome, using medication that prolongs QT internal, OR evidence of prolonged QT of >470 msec as evidenced by ECG
- Pregnant/nursing women
Where in United States
- Zuckerberg San Francisco General HospitalSan Francisco, United States
About the trial
What the trial wants to find out
This study is a double blinded, placebo-controlled, randomized, parallel group study, designed to compare the efficacy and safety of VB-201 80mg taken orally once daily to placebo for anti-inflammation in HIV-infected subjects.
The 2 groups in the trial
- VB-201Treatment being tested
One dose of VB-201 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
- PlaceboPlacebo, for comparison
One dose of placebo 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 15 September 2022